The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
After the riots, the controversial New Economic Policy was launched by Prime Minister Tun Abdul Razak, trying to increase the share of the economy held by the bumiputera. Under Prime Minister Mahathir Mohamad there was a period of rapid economic growth and urbanisation beginning in the 1980s. The economy shifted from being agriculturally based to one based on manufacturing and industry. Numerous mega-projects were completed, such as the Petronas Towers, the North–South Expressway, the Multimedia Super Corridor, and the new federal administrative capital of Putrajaya. In the late 1990s, the Asian financial crisis impacted the country, nearly causing their currency, stock, and property markets to crash; however, they later recovered. The 1MDB scandal was a major global corruption scandal that implicated then-Prime Minister Najib Razak in 2015. The scandal contributed to the first change in the ruling political party since independence in the 2018 general election. In the 2020s, the country was gripped by a political crisis that coincided with health and economic crises caused by the COVID-19 pandemic. This was then followed by an earlier general election in November 2022, which resulted in the first hung parliament in the nation's history. On 24 November 2022, Anwar Ibrahim was sworn in as the 10th Prime Minister of Malaysia, leading a grand coalition government.
It is known also as simpler's joy or holy herb, or more ambiguously as mosquito plant or wild hyssop. The common name blue vervain is also sometimes used, but also refers to V. hastata. Being the only member of its genus in much of its range, it is also simply known as vervain locally. The common names of V. officinalis in many Central and Eastern European languages often associate it with iron, for example:
In the Middle Ages the regions situated on the mountainous border of the Duchy and the Kingdom of Bohemia (Crown of Saint Václav) had since the Migration Period been settled mainly by western Slavic Czechs. Along the Bohemian Forest in the west, the Czech lands bordered on the German Slavic tribes (German Sorbs) stem duchies of Bavaria and Franconia; marches of the medieval German kingdom had also been established in the adjacent Austrian lands south of the Bohemian-Moravian Highlands and the northern Meissen region beyond the Ore Mountains. In the course of the Ostsiedlung (settlement of the east), German settlement from the 13th century onwards continued to move into the Upper Lusatia region and the duchies of Silesia north of the Sudetes mountain range. From as early as the second half of the 13th century onwards these Bohemian border regions were settled by ethnic Germans, who were invited by the Přemyslid Bohemian kings—especially by Ottokar II (1253–1278) and Wenceslaus II (1278–1305). After the extinction of the Přemyslid dynasty in 1306, the Bohemian nobility backed John of Luxembourg as king against his rival Duke Henry of Carinthia. In 1322, King John of Bohemia acquired (for the third time) the formerly Imperial Egerland region in the west and vassalized most of the Piast Silesian duchies, as acknowledged by King Casimir III of Poland by the 1335 Treaty of Trentschin. His son, Bohemian King Charles IV, was elected King of the Romans in 1346 and crowned Holy Roman Emperor in 1355.
== Limitations == FFF does not work for small molecules, because of their fast diffusion. For an effective separation, the sample has to be concentrated very close to the accumulation wall (a distance less than 10 μm), which requires the drift velocity caused by the force field to be two orders of magnitude higher compared to the diffusion coefficient. The maximum field strength which can be generated in an FFF channel determines the lower size range of separation. For current instrumentation this is approximately 1 nm. Although FFF is an extremely versatile technique, there is no "one size fits all" method for all applications. Different FFF methods need specialized instrumentation. Currently only the so-called asymmetric flow field-flow fractionation (AF4) has gained widespread use. Other methods like centrifugal, thermal or electrical FFF still have a niche existence. FFF behaves differently from column chromatography and can be counter-intuitive for HPLC or SEC users. Understanding of the working principle of FFF is vital for a successful application of the method.
Sources: en.wikipedia.org
== Epidemiology == The HbS gene can be found in every ethnic group. The highest frequency of sickle cell disease is found in tropical regions, particularly sub-Saharan Africa, tribal regions of India, and the Middle East. About 80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa. Migration of substantial populations from these high-prevalence areas to low-prevalence countries in Europe has dramatically increased in recent decades and in some European countries, sickle cell disease has now overtaken more familiar genetic conditions such as haemophilia and cystic fibrosis. In 2015, it resulted in about 114,800 deaths. Sickle cell disease occurs more commonly among people whose ancestors lived in tropical and subtropical sub-Saharan regions where malaria is or was common. Where malaria is common, carrying a single sickle cell allele (trait) confers a heterozygote advantage; humans with one of the two alleles of sickle cell disease show less severe symptoms when infected with malaria. This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Miller (1992), professor of law at the University of Iowa Matthew Shum (1992), professor of economics at California Institute of Technology Victor Fleischer (1993), professor of law at University of California, Irvine Valerie Purdie Greenaway (1993), professor of psychology and first African-American to receive tenure in the sciences at Columbia University Michelle Hartman (1993), professor of Arabic and francophone literature at McGill University Soyoung Lee (1993), chief curator of the Harvard Art Museums Seth Rockman (1993), professor at Brown University, co-recipient of the 2010 Merle Curti Award David Rosen (1993), professor at Trinity College, Connecticut, recipient of the 2013 James Russell Lowell Prize David Eisenbach (1994), historian on media and politics; narrator, 10 Things You Don't Know About François Furstenberg (1994), historian at Johns Hopkins University Katerina Harvati (1994), professor of paleoanthropology at the University of Tübingen, identified the earliest known sample of the remains of modern humans outside Africa Ayanna Thompson (1994), professor of English at Arizona State University, president of the Shakespeare Association of America David H.
Phlebotomy is the process of making a puncture in a vein, usually in the arm or hand, with a cannula for the purpose of drawing blood. The procedure itself is known as a venipuncture, which is also used for intravenous therapy. A person who performs a phlebotomy is called a phlebotomist, although most doctors, nurses, and other technicians can also carry out a phlebotomy. In contrast, phlebectomy is the removal of a vein. Phlebotomies that are carried out in the treatment of some blood disorders are known as therapeutic phlebotomies. The average volume of whole blood drawn in a therapeutic phlebotomy to an adult is 1 unit (450–500 ml) weekly to once every several months, as needed.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.